Premium
Omeprazole, bismuth and clarithromycin in the sequential treatment of Helicobacter pylori infection
Author(s) -
NERI M.,
SUSI D.,
LATERZA F.,
IORIO P.,
SECCIA G.,
MEZZETTI A.,
CUCCIIRULLO F.
Publication year - 1994
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1994.tb00317.x
Subject(s) - omeprazole , clarithromycin , helicobacter pylori , medicine , gastroenterology , gastritis , spirillaceae , antibacterial agent , antibiotics , microbiology and biotechnology , biology
SUMMARY Aims: To assess the therapeutic potential of clarithromycin, a new macrolide with high anti‐ Helicobacter pylori activity, given with bismuth salts and omeprazole in different regimens aimed at simplifying the treatment of H. piylon‐related gastritis. Methods: Eighty‐eight patients with proven H. pylori infection and gastritis were treated with one of the following four regimens: omeprazole 40 mg/day for one week (group A. n = 14); omeprazole 40 mg/day for one week followed by clarithromycin 1 g/day for 2 weeks (group B, n = 26); omeprazole 40 mg/day for one week followed by tripotassium dicitrato bismuthate 480 mg/day and clarithromycin 1 g/day, both for two weeks (group C, n = 26); and tripotassium dicitrato bismuthate 480 mg/day and clarithromycin 1 g/day for two weeks (group D, n = 22). Presence of H. pylori , histology and electron microscopy were assessed at entry and four weeks after the end of each treatment. Results: Omeprazole alone had no effect on H. pylori status. The highest eradication rate was obtained in group C patients (81%), a proportion significantly greater than that observed in group B (50%, P < 0.03) or group D patients (55%, P < 0.05). Conclusion: Sequential treatment may be a useful option in the treatment of H. pylori‐related gastritis.